Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 8:10:533.
doi: 10.3389/fonc.2020.00533. eCollection 2020.

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review

Roberta Lombardo  1   2 , Federica Tosi  1   2 , Annunziata Nocerino  1 , Katia Bencardino  1 , Valentina Gambi  1 , Riccardo Ricotta  1 , Francesco Spina  1 , Salvatore Siena  1   2 , Andrea Sartore-Bianchi  1   2
Affiliations

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review

Roberta Lombardo et al. Front Oncol. .

Abstract

Background: Carcinomas of unknown primary (CUP) account for 3-5% of all malignancy and, despite a reduction in incidence, the overall survival has not improved over the last decade. Chemotherapy regimens have not provided encouraging results. New diagnostic technologies, such as next generation sequencing (NGS), could represent a chance to identify potentially targetable genomic alterations in order to personalize treatment of CUP and provide insights into tumor biology. Methods: A systematic review of studies of patients with CUP, whose tumor specimen was evaluated through a NGS panel, has been performed on June 10th, 2019 according to PRISMA criteria from PubMed, ASCO meeting library and Clinicaltrial.gov. We have identified potentially targetable alterations for which approved/off-label/in clinical trials drugs are available. Moreover, we have included case reports about CUP patients treated with targeted therapies driven by NGS results in order to explore the clinical role of NGS in this setting. Results: We have evaluated 15 publications of which eleven studies (9 full-text articles and 2 abstracts) have analyzed the genomic profiling of CUPs through NGS technology, with different platforms and with different patients cohorts, ranging from 16 to 1,806 patients. Among all these studies, 85% of patients demonstrated at least one molecular alteration, the most frequent involving TP53 (41.88%), KRAS (18.81%), CDKN2A (8.8%), and PIK3CA (9.3%). A mean of 47.3% of patients harbored a potentially targetable alteration for which approved/off-label/in clinical trials drugs were available. Furthermore, we have identified 4 case reports in order to evaluate the clinical relevance of a specific targeted therapy identified through NGS. Conclusions: NGS may represent a tool to improve diagnosis and treatment of CUP by identifying therapeutically actionable alterations and providing insights into tumor biology.

Keywords: cancer of unknown primary (CUP); comprehensive genomic profiling; genomic alterations; next generation sequencing (NGS); targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram representing the systematic review process performed according to PRISMA Statement (13).
See this image and copyright information in PMC

References

    1. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2015) 26:v133–8. 10.1093/annonc/mdv305 - DOI - PubMed
    1. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer. (2002) 38:1810–2. 10.1016/S0959-8049(02)00135-1 - DOI - PubMed
    1. Mnatsakanyan E, Tung W-C, Caine B, Smith-Gagen J. Cancer of unknown primary: time trends in incidence, United States. Cancer Causes Control. (2014) 25:747–57. 10.1007/s10552-014-0378-2 - DOI - PubMed
    1. Binder C, Matthes KL, Korol D, Rohrmann S, Moch H. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med. (2018) 7:4814–24. 10.1002/cam4.1689 - DOI - PMC - PubMed
    1. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JPA, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. (2009) 35:570–3. 10.1016/j.ctrv.2009.05.005 - DOI - PubMed

Publication types